Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (7): 582-585.doi: 10.35541/cjd.20201261
• Original Articles • Previous Articles Next Articles
Zhang Yu, Gao Yingxia, Gu Ningyan, Zhu Hong, Chen Jingjing, Hu Qingjie, Zhou Min, Duan Yuanyuan, Yao Xu
Received:
2020-12-31
Revised:
2021-04-11
Online:
2021-07-15
Published:
2021-07-02
Contact:
Yao Xu
E-mail:dryao_xu@126.com
Supported by:
Zhang Yu, Gao Yingxia, Gu Ningyan, Zhu Hong, Chen Jingjing, Hu Qingjie, Zhou Min, Duan Yuanyuan, Yao Xu. Clinical efficacy and safety of omalizumab in the treatment of chronic spontaneous urticaria[J]. Chinese Journal of Dermatology, 2021, 54(7): 582-585.doi:10.35541/cjd.20201261
[1] | Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta⁃analysis[J]. Allergy, 2020,75(2):423⁃432. doi: 10.1111/all.14037. |
[2] | Xiao Y, Huang X, Jing D, et al. The prevalence of atopic dermatitis and chronic spontaneous urticaria are associated with parental socioeconomic status in adolescents in China[J]. Acta Derm Venereol, 2019,99(3):321⁃326. doi: 10.2340/000155 55⁃3104. |
[3] | Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy[J]. J Allergy Clin Immunol, 2013,132(1):101⁃109. doi: 10.1016/j.jaci.2013.05.013. |
[4] | Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo⁃controlled, dose⁃ranging study of single⁃dose omalizumab in patients with H1⁃antihistamine⁃refractory chronic idiopathic urticaria[J]. J Allergy Clin Immunol, 2011,128(3):567⁃573.e1. doi: 10.1016/j.jaci.2011.06.010. |
[5] | Maurer M, Kaplan A, Rosén K, et al. The XTEND⁃CIU study: long⁃term use of omalizumab in chronic idiopathic urticaria[J]. J Allergy Clin Immunol, 2018,141(3):1138⁃1139.e7. doi: 10.1016/ j.jaci.2017.10.018. |
[6] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[7] | Guntern P, Eggel A. Past, present, and future of anti⁃IgE biologics[J]. Allergy, 2020,75(10):2491⁃2502. doi: 10.1111/all.14308. |
[8] | Larenas⁃Linnemann D, Parisi C, Ritchie C, et al. Update on omalizumab for urticaria: what′s new in the literature from mechanisms to clinic[J]. Curr Allergy Asthma Rep, 2018,18(5):33. doi: 10.1007/s11882⁃018⁃0787⁃5. |
[9] | Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2017,140(6):1749⁃1751. doi: 10.1016/j.jaci.2017.08.007. |
[10] | 陈玉迪, 耿鹏, 赵嘉惠, 等. 慢性自发性荨麻疹: 奥马珠单抗治疗作用机制与疗效评估[J]. 中华皮肤科杂志, 2019,52(9):652⁃655. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.014. |
[11] | Eghrari⁃Sabet J, Sher E, Kavati A, et al. Real⁃world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States[J]. Allergy Asthma Proc, 2018,39(3):191⁃200. doi: 10.2500/aap.2018.39.4132. |
[12] | Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: real life experience with twenty⁃five patients[J]. Allergol Int, 2018,67(1):85⁃89. doi: 10.1016/j.alit.2017.05.003. |
[1] | Wang Juanjuan, Chen Rong, Ji Jiang, Su Wenxing, Wei Yuqian, Zhao Ying, Yin Xingping, Su Yuhua, Shi Xin. Retrospective analysis of 67 cases of neurosyphilis with abnormal mental behaviors as the initial symptom [J]. Chinese Journal of Dermatology, 2022, 55(3): 231-234. |
[2] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
[3] | Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245. |
[4] | Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263. |
[5] | Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218. |
[6] | Wang Jiaqi, Wang Ping, Li Liuyu, Fan Qimin, Zhu Mengyan, Wang Yanqing, Zhou Hongyu, Shen Hong, Xu Ai′e. Cutaneous hypopigmented lymphoproliferative disorders: a clinicopathological study of 41 cases [J]. Chinese Journal of Dermatology, 2022, 55(2): 110-115. |
[7] | Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631. |
[8] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
[9] | Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644. |
[10] | Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64. |
[11] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420. |
[12] | Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75. |
[13] | Guo Wei, Zhao Tao, Guo Weinan, Ma Cuiling, Gao Tianwen, Zhao Jianhong, Li Bing. Surgical treatment strategies and outcomes of early-stage nail apparatus melanoma: a retrospective analysis of 115 cases [J]. Chinese Journal of Dermatology, 2021, 54(9): 777-784. |
[14] | Yang Min, Chang Jianmin. Imatinib-induced cutaneous adverse reactions [J]. Chinese Journal of Dermatology, 2021, 54(8): 738-741. |
[15] | Yu Yingyuan, Li Ying, Yu Zengyang, Zheng Jianfeng, Zhang Xilin, Ding Yangfeng, Shi Yuling, . Efficacy and safety of infliximab in the treatment of severe plaque psoriasis and its effect on the expression of programmed cell death-1 and programmed cell death ligand-1 [J]. Chinese Journal of Dermatology, 2021, 54(7): 590-596. |
|